Alk and ros kinase in cancer

Patent metadata

Field	Value
Publication number	US-2017275706-A1
Application number	US-201715616111-A
Country	US
Kind code	A1
Filing date	Jun 7, 2017
Priority date	May 21, 2010
Publication date	Sep 28, 2017
Grant date	—

Abstract

The invention provides a method for identifying a patient with cancer or suspected of having cancer as a patient likely to respond to an ALK- and/or ROS-inhibiting therapeutic, comprising: contacting a biological sample from a patient with a first reagent that specifically binds a polypeptide having ROS kinase activity and a second reagent that specifically binds to a polypeptide having ALK knase activity, and detecting whether the first reagent or the second reagent specifically binds to the biological sample, wherein detection of binding of either the first reagent or the second reagent to the biological sample identifies the patient as a patient likely to respond to an ALK-inhibiting and/or ROS-inhibiting therapeutic.

First claim

1 . A method of treating a patient for cancer, comprising:
detecting the presence in a biological sample from a patient having or suspected of having cancer of a polypeptide selected from the group consisting of a polypeptide having ROS kinase activity and a polypeptide having ALK kinase activity; and administering a therapeutically effective amount of an ALK- and/or ROS-inhibiting therapeutic to the patient, thereby treating the patient for cancer.

2 . The method of claim 1 , wherein the detecting step is performed by using a reagent that specifically binds to a polynucleotide encoding either a polypeptide having ROS kinase activity or a polypeptide having ALK kinase activity.

3 . The method of claim 1 , wherein the detecting step is performed by using a reagent that specifically binds to either a polypeptide having ROS kinase activity or a polypeptide having ALK kinase activity.

4 . A method for identifying a patient with cancer or suspected of having cancer as a patient likely to respond to an ALK-inhibiting and/or a ROS-inhibiting therapeutic, comprising:
contacting a biological sample from a patient with a first reagent that specifically binds a polypeptide having ROS kinase activity and a second reagent that specifically binds to a polypeptide having ALK knase activity, and detecting whether the first reagent or the second reagent specifically binds to the biological sample, wherein detection of binding of either the first reagent or the second reagent to the biological sample identifies the patient as a patient likely to respond to an ALK- and/or ROS-inhibiting therapeutic.

5 . A method for identifying a patient with cancer or suspected of having cancer as a patient likely to respond to an ALK- and/or ROS-inhibiting therapeutic, comprising:
contacting a biological sample from a patient with a first reagent that specifically binds a polypeptide having ROS kinase activity or specifically binds to a polynucleotide encoding a polypeptide having ROS kinase activity and a second reagent that specifically binds to a polypeptide having ALK knase activity or specifically binds to a polynucleotide encoding a polypeptide having ALK kinase activity, and detecting whether the first reagent or the second reagent specifically binds to the biological sample, wherein detection of binding of either the first reagent or the second reagent to the biological sample identifies the patient as a patient likely to respond to an ALK- and/or ROS-inhibiting therapeutic.

6 . The method of claim 4 or 5 , wherein the first reagent specifically binds to full length ROS kinase protein.

7 . The method of claim 4 or 5 , wherein the second reagent specifically binds to full length ALK kinase protein.

8 . The method of claim 4 or 5 , wherein the first reagent specifically binds to the kinase domain of ROS kinase protein.

9 . The method of claim 4 or 5 wherein the second reagent specifically binds to the kinase domain of ALK kinase protein.

10 . The method of claim 4 or 5 wherein the first reagent is an antibody.

11 . The method of claim 4 or 5 wherein the second reagent is an antibody.

12 . The method of claim 3 , wherein the reagent is an antibody.

13 . The method of claim 2 , wherein the reagent is a nucleic acid probe.

14 . The method of claim 4 or 5 , wherein the reagent is a nucleic acid probe.

15 . The method of claim 4 or 5 , wherein the reagent is a nucleic acid probe.

16 . The method of claim 1 , 4 , or 5 , wherein the patient is a human patient.

17 . The method of claim 1 , 4 , or 5 , wherein the cancer or suspected cancer is from a human.

18 . The method of claim 1 , 4 , or 5 , wherein the ROS-inhibiting therapeutic or the ALK-inhibiting therapeutic is PF-02341066, NVT TAE-684, AP26113, CEP-14083, CEP-14513, CEP11988, CH5424802, WHI-P131 and WHI-P154.

19 . The method of claim 1 , 4 , or 5 , wherein the biological sample is from the cancer or suspected cancer of the patient.

20 . The method of claim 1 , 4 , or 5 , wherein the cancer is a solid tumor cancer.

21 . The method of claim 1 , 4 , or 5 , wherein the cancer is leukemia or lymphoma.

22 . The method of claim 1 , 4 , or 5 , wherein the cancer is lung cancer, brain cancer, liver cancer, colon cancer, kidney cancer, breast cancer or ovarian cancer.

23 . The method of claim 1 , 4 , or 5 , wherein the biological sample is selected from the group consisting of a tumor biopsy, a bronchoalveolar lavage, a circulating tumor cell, a tumor resection, a fine needle aspirate, a lymph node, a bone marrow sample, and an effusion (e.g., pleural effusion).

24 . The method of claim 1 , 4 , or 5 , wherein the reagents are detectably labeled.

25 . The method of claim 1 , 4 , or 5 , wherein the polypeptide having ROS kinase activity is a full-length ROS polypeptide or is a ROS fusion polypeptide.

26 . The method of claim 1 , 4 , or 5 , wherein the polypeptide having ALK kinase activity is full length ALK polypeptide or is an ALK fusion polypeptide.

27 . The method of claim 1 , 4 , or 5 , wherein the method is implemented in a format selected from the group consisting of a flow cytometry assay, an in vitro kinase assay, an immunohistochemistry (IHC) assay, an immunofluorescence (IF) assay, an Enzyme-linked immunosorbent assay (ELISA) assay, and a Western blotting analysis assay.

28 . The method of claim 2 or 5 , wherein the reagent is detectably labeled.

29 . The method of claim 2 or 5 , wherein the reagent is a fluorescence in-situ hybridization (FISH) probe and said method is implemented in a FISH assay.

30 . The method of claim 2 or 5 , wherein the reagent is a polymerase chain reaction (PCR) probe and said method is implemented in a PCR assay.

31 . A method for inhibiting the progression of a mammalian cancer or suspected mammalian cancer that expresses either a first polypeptide having ROS kinase activity or a second polypeptide having ALK kinase activity, said method comprising the step of inhibiting the expression and/or activity of said first or said second polypeptide in said mammalian cancer or suspected mammalian cancer.

32 . A method for inhibiting the progression of a mammalian cancer or suspected mammalian cancer comprising a first polynucleotide encoding a polypeptide having ROS kinase activity or a second polynucleotide encoding a polypeptide having ALK kinase activity, said method comprising the step of inhibiting the expression of said first or said second polynucleotide in said mammalian cancer or suspected mammalian cancer.

33 . The method of claim 31 or 32 , wherein the mammalian cancer or suspected mammalian cancer is from a human.

Assignees

• Cell Signaling Technology Inc

Inventors

• Rimkunas Victoria Mcguinness
• Haack Herbert
• Crosby Katherine Eleanor

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• C12Q1/485

  involving kinase · CPC title

• G01N2333/71

  for growth factors; for growth regulators · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title